Big pharma’s key second-quarter data

The second quarter promises several important oncology readouts for Roche, including data from the anti-Tigit tiragolumab, a key pipeline asset. And results from the company's oral Serd will show whether giredestrant can avoid the same fate as Sanofi’s recently failed amcenestrant.

Elsewhere, Lilly will hope that tirzepatide can take on Novo Nordisk in obesity with data from the project’s first pivotal study in this setting, while Glaxosmithkline and Pfizer head towards readouts in respiratory syncytial virus (RSV).